^
Association details:
| Biomarker: | EML4-ALK variant 3 |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Alecensa (alectinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Complete pathologic response to short-course neoadjuvant alectinib in mediastinal node positive (N2) ALK rearranged lung cancer
Published date:
08/23/2022
Excerpt:
A case with stage IIIA (cT1b cN2 cM0) EML4-ALK variant 3a/b lung adenocarcinoma received 6 weeks of alectinib followed by R0 left upper lobectomy with complete pathological response (ypT0 ypN0).
DOI:
https://doi.org/10.1016/j.lungcan.2022.08.014
Source:
Title:
EP16.03-012 - Novel Human-derived EML4-ALK Fusion cell lines identify ribonucleotide reductase RRM2 as a Target of Activated ALK in NSCLC
Published date:
07/12/2022
Excerpt:
In this study, we have confirmed the expression of the corresponding ALK fusion protein and assessed their sensitivity to a range of ALK tyrosine kinase inhibitors (TKIs). These patient-derived cell lines exhibit differential sensitivity to ALK TKIs, such as lorlatinib, brigatinib and alectinib, with EML4-ALK variant 3 containing cell lines exhibiting an increased sensitivity to lorlatinib and brigatinib as compared to alectinib.
